M.D. Sass Equity Income Plus Fund

Overview | Fund Facts & Characteristics | Performance | Holdings & Sectors | Fact Sheets

As of 6/30/17

Top 10 Holdings

Name Ticker        
Gilead Sciences, Inc. GILD
NRG Yield, Inc. NYLD
Covanta Holding Corp. CVA
Macquarie Infrastructure Corp. MIC
Delta Air Lines, Inc. DAL
Discover Financial Services DFS
Pfizer Inc. PFE
Royal Caribbean Cruises Ltd. RCL
Allergan PLC AGN
CVS Health Corp. CVS
   
Total 40.1%

Sectors

Fund holdings and sector allocations are subject to change at any time and are not recommendations to buy or sell any security.

The S&P 500 Index is a broad based unmanaged index of 500 stocks, which is widely recognized as representative of the equity market in general. You cannot invest directly in an index.

For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating (based on a Morningstar risk-adjusted return measure that accounts for variation in a fund's monthly performance, including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. As of 6/30/17, the MD Sass Short Term US Government Agency Income Fund was rated 3-Stars against the following numbers of Short Government funds over the following time periods: 105 funds in the last three- and 95 funds in the last five-years. The M.D. Sass Equity Income Plus Fund (Institutional Class) was rated 2 stars against the following numbers of Option Writing Funds over the following time periods: 76 funds in the last three years.

Morningstar Rating

MDEIX 2-Star Overall Morningstar Rating™ as of 6/30/17 out of 76 Option Writing Funds.

The Overall Morningstar Rating™ for a fund is derived from a weighted average of the fund's three-year Morningstar Rating™ metrics, which are based on risk-adjusted return performance.